FDA Approves RU-486
WASHINGTON - The Food and Drug Administration (FDA) approved the abortion pill RU-486. Within a month, doctors will be able to prescribe the drug Mifeprex, or mifepristone, for women who are as much as seven weeks pregnant.
Despite warnings that the FDA would impose limitations on doctors who offer the pill, yesterdays approval came with relatively minor restrictions. The rules given require that doctors who prescribe Mifeprex be able to determine how far along a pregnancy is and must either be able to perform surgical abortions or have a pre-existing agreement with another physician who is qualified to conduct such surgery. For more information visit www.fda.gov.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
